TransCode Therapeutics Stock (NASDAQ:RNAZ)


RevenueOwnershipFinancialsChart

Previous Close

$0.61

52W Range

$0.22 - $21.20

50D Avg

$0.32

200D Avg

$1.22

Market Cap

$10.17M

Avg Vol (3M)

$1.93M

Beta

0.63

Div Yield

-

RNAZ Company Profile


TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Jul 08, 2021

Website

RNAZ Performance


RNAZ Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-18.55B$-18.67M$-6.15M
Net Income$-18.55B$-35.13M$-6.94M
EBITDA$-18.55B$-17.47M$-5.83M
Basic EPS$-103.61$-2.17K$-430.16
Diluted EPS$-103.61$-2.17K$-430.16

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 21Apr 07, 22 | 7:05 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
ONCROncorus, Inc.
XBIOXenetic Biosciences, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
LABPLandos Biopharma, Inc.
KODKodiak Sciences Inc.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
EYENEyenovia, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
CGTXCognition Therapeutics, Inc.
ZURAZura Bio Limited